ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2875

Macrophage Expression of Hypoxia-Inducible Factor-2 Alpha Promotes Rheumatoid Arthritis Progression

Munitta Muthana1,2, William Jacob Hardy3, Sarah Hawtree1, Fiona Wright1, Ursula Fearon4, DJ Veale5, Mauro Perretti6 and Anthony G. Wilson7, 1Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, 2Medical School, University of Sheffield, Sheffield, United Kingdom, 3University of Sheffield, Sheffield, United Kingdom, 4Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland, 5Consultant Rheumatologist, St. Vincent’s University Hospital, Dublin, Ireland, 6Biochemical Pharmaology, Barts and the London School of Medicine, London, United Kingdom, 7University College Dublin, Dublin, Ireland

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: macrophages

  • Tweet
  • Email
  • Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II

Session Type: Abstract Submissions (ACR)

Background/Purpose

Hypoxia exists in many diseased tissues including arthritic joints, atherosclerotic plaques and malignant tumours. Macrophages accumulate in these hypoxic sites where they possess broad pro-inflammatory, destructive and remodelling potential leading to inflammation and joint destruction. Macrophages respond to hypoxia by up regulating the hypoxia inducible transcription factors– HIF-1 and -2, which leads to the up-regulation of genes involved in proliferation, angiogenesis, and glucose metabolism.

The purpose of our study was to characterise the HIF-2 expressing macrophage populations in response to joint hypoxia, and in particular to dissect out the effects of HIF-2 in a murine model of arthritis.

Methods

Arthroscopy sections from RA patients with mild (~40mmHg) or severe (~3mmHg) joint hypoxia were immunostained with anti-HIF 2 and co-localised with the pan-macrophage marker CD68 as well as other M1 and M2 macrophage markers. Cell-specific RNA was purified from CD68+ve macrophages in RA tissue by laser capture microdissection (LCM) and differential gene expression was determined using the RT2 Profiler PCR inflammatory arrays. The significance of HIF-2 was also evaluated in the K/BxN serum transfer model in mice bearing a targeted deletion of HIF-2 in myeloid cells including macrophages (HIF2fl/fl; LysM-Cre+’ mice). Arthritis was assessed clinically and histologically.

Results

In patients with severely hypoxic joints macrophages predominately expressed HIF-2 as well receptors for VEGF (Flt1), angiopoietin ‘Tie2’ and mannose ‘CD206’ markers associated with M2-skewed macrophages. However, expression of CXCL-2, -4, -5, IL-1a, IL-6 IL-8 & TNFa were also all up regulated compared to macrophages from mildly hypoxic joints. In vivo, macrophages lacking HIF2 significantly suppressed disease development indicating an indispensable role for HIF2 in supporting macrophages in K/BxN serum-transfer arthritis.

Conclusion

HIF-2 expressing macrophages have an M1 & M2-like phenotype in patients with severely hypoxic joints and loss of HIF-2 in macrophages suppressed arthritis in mice. Collectively, our data identify HIF-2 as an important regulator of macrophage function, suggesting it may be a useful therapeutic target for treating RA.


Disclosure:

M. Muthana,
None;

W. J. Hardy,
None;

S. Hawtree,
None;

F. Wright,
None;

U. Fearon,
None;

D. Veale,
None;

M. Perretti,
None;

A. G. Wilson,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/macrophage-expression-of-hypoxia-inducible-factor-2-alpha-promotes-rheumatoid-arthritis-progression/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology